From Obesity to Efficacy: A Comprehensive Analysis of Emerging Weight Loss Drugs
Hani Raka Karrar
*
Pharmaceutical Care Services, Dr. Samir Abbas Hospital, Jeddah, Saudi Arabia.
Mahmoud Ismail Nouh
Chairman of Research and Continues Education Committees in Pharmacy Department at King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.
Sarah abdulhadi Alanazi
Pharmacy Department, Aldawa Company, Arar, Saudi Arabia.
Wasan Salman Alanazi
Pharmaceutical Care Services, Northern Border Region, Arar, Kingdom of Saudi Arabia.
ABDELBAGI ABDELMAGEED MOHAMMED ABDELMAGEED
Surgical Department, Abha Private Hospital, Abha, Saudi Arabia.
Amuna Hamad Awaji
Nursing Department, King Fahd Security College Medical Center, Riyadh, Saudi Arabia.
Yassir abubakar fikak
Department of Pharmacology, Saharanpur, Uttar Pradesh, India.
Barakat Ali Alshmrany
Pharmaceutical Care Services, Northern Area Armed Forces Hospital, Northern Area, Saudi Arabia.
*Author to whom correspondence should be addressed.
Abstract
Obesity has emerged as a critical global health crisis in the 21st century, as defined by the World Health Organization (WHO) with a body mass index (BMI) of 30 or higher. This condition greatly raises the risk of getting a number of long-term diseases, such as type 2 diabetes, heart disease, high blood pressure, and many types of cancer. In the last few decades, obesity has become much more common, almost tripling since 1975. Poor diet, lack of exercise, mental health problems, and socio-economic problems are all factors that contribute to the epidemic's complexity. To deal with obesity, we need a comprehensive approach that includes changes to our lifestyle, psychological support, and medicine. Making changes to your lifestyle, like eating better and getting more exercise, is a key part of managing your weight, but they often don't work for many people, especially those who are very overweight. As a result, pharmacotherapy has become an essential tool, particularly for individuals who have not achieved significant weight loss through non-pharmacological means. Traditional weight loss medications, such as phentermine and orlistat, have paved the way for current treatments but are often limited by adverse effects and varying efficacy across patients. This has spurred an increase in research and development focused on novel agents. Among these, GLP-1 receptor agonists—like semaglutide—have shown significant promise, alongside newer combination therapies that target various biological mechanisms involved in weight regulation. These contemporary pharmacological options not only facilitate weight loss but also aim to address underlying metabolic and psychological factors that contribute to obesity. Moreover, the ever-changing treatment environment indicates an alignment toward comprehensive management strategies that are more adaptable towards the complexities associated with obesity. In other words, the comprehensive treatment approach indicates promise in improving treatment outcomes, minimizing the risks of obesity as an underlying cause for various health ailments, and finally mitigating the adverse effects that come along with this harmful health issue. In the ongoing process of unraveling further studies, the effectiveness of customized treatment plans, which include pharmacological management, lifestyle, and psychology, becomes paramount in the ongoing battle against the prevalence of obesity.
Keywords: Obesity, Body Mass Index (BMI), chronic illnesses, public health, weight management, pharmacotherapy